These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

706 related items for PubMed ID: 19535242

  • 1. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.
    Alkner S, Bendahl PO, Fernö M, Nordenskjöld B, Rydén L, South Swedish and South-East Swedish Breast Cancer Groups.
    Eur J Cancer; 2009 Sep; 45(14):2496-502. PubMed ID: 19535242
    [Abstract] [Full Text] [Related]

  • 2. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    International Breast Cancer Study GroupDivision of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. marco.colleoni@ieo.it, Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD.
    J Clin Oncol; 2006 Mar 20; 24(9):1332-41. PubMed ID: 16505417
    [Abstract] [Full Text] [Related]

  • 3. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up.
    Rydén L, Jönsson PE, Chebil G, Dufmats M, Fernö M, Jirström K, Källström AC, Landberg G, Stål O, Thorstenson S, Nordenskjöld B, South Swedish Breast Cancer Group, South-East Swedish Breast Cancer Group.
    Eur J Cancer; 2005 Jan 20; 41(2):256-64. PubMed ID: 15661551
    [Abstract] [Full Text] [Related]

  • 4. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L, Landberg G, Stål O, Nordenskjöld B, Fernö M, Bendahl PO.
    Breast Cancer Res Treat; 2008 May 20; 109(2):351-7. PubMed ID: 17636399
    [Abstract] [Full Text] [Related]

  • 5. The effect of adjuvant tamoxifen: the latest results from the Cancer Research Campaign Adjuvant Breast Trial. Cancer Research Campaign Breast Cancer Trials Group.
    Eur J Cancer; 1992 May 20; 28A(4-5):904-7. PubMed ID: 1524921
    [Abstract] [Full Text] [Related]

  • 6. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer.
    Rutqvist LE, Johansson H, Stockholm Breast Cancer Study Group.
    Acta Oncol; 2007 May 20; 46(2):133-45. PubMed ID: 17453361
    [Abstract] [Full Text] [Related]

  • 7. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
    Rydén L, Jirström K, Bendahl PO, Fernö M, Nordenskjöld B, Stål O, Thorstenson S, Jönsson PE, Landberg G.
    J Clin Oncol; 2005 Jul 20; 23(21):4695-704. PubMed ID: 16034044
    [Abstract] [Full Text] [Related]

  • 8. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P, Paridaens R, European Organisation for Research and Treatment of Cancer Breast Group, Scottish Breast Cancer Trials Group.
    Eur J Cancer; 2007 Jan 20; 43(2):331-40. PubMed ID: 17134892
    [Abstract] [Full Text] [Related]

  • 9. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK.
    J Clin Oncol; 2005 Jul 20; 23(21):4687-94. PubMed ID: 15837971
    [Abstract] [Full Text] [Related]

  • 10. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.
    J Natl Cancer Inst; 2005 Nov 16; 97(22):1652-62. PubMed ID: 16288118
    [Abstract] [Full Text] [Related]

  • 11. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.
    Sverrisdottir A, Johansson H, Johansson U, Bergh J, Rotstein S, Rutqvist L, Fornander T.
    Breast Cancer Res Treat; 2011 Aug 16; 128(3):755-63. PubMed ID: 21625929
    [Abstract] [Full Text] [Related]

  • 12. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M, Kodama T.
    In Vivo; 2001 Aug 16; 15(4):319-25. PubMed ID: 11695224
    [Abstract] [Full Text] [Related]

  • 13. [The effect of long-term tamoxifen therapy on the occurrence of contralateral primary breast cancer].
    Xing B, Huang X, Wang Y.
    Zhonghua Zhong Liu Za Zhi; 1996 Mar 16; 18(2):143-5. PubMed ID: 9206051
    [Abstract] [Full Text] [Related]

  • 14. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, Ellard S, Norris B, Hayes M, Barnett J, Gelmon KA.
    Cancer; 2008 Apr 01; 112(7):1437-44. PubMed ID: 18286526
    [Abstract] [Full Text] [Related]

  • 15. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer.
    Giltnane JM, Rydén L, Cregger M, Bendahl PO, Jirström K, Rimm DL.
    J Clin Oncol; 2007 Jul 20; 25(21):3007-14. PubMed ID: 17634479
    [Abstract] [Full Text] [Related]

  • 16. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB, Feuer EJ, Harlan LC, Abrams J.
    J Natl Cancer Inst Monogr; 2006 Jul 20; (36):7-15. PubMed ID: 17032888
    [Abstract] [Full Text] [Related]

  • 17. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.
    Love RR, Van Dinh N, Quy TT, Linh ND, Tung ND, Shen TZ, Hade EM, Young GS, Jarjoura D.
    J Clin Oncol; 2008 Jan 10; 26(2):253-7. PubMed ID: 18086800
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, Baak JP, Søreide JA.
    Acta Oncol; 2009 Jan 10; 48(4):514-21. PubMed ID: 19107621
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.